Kymera Therapeutics Inc’s recent filing unveils that its Director BAKER BROS. ADVISORS LP acquired Company’s shares for reported $28.84 million on Jun 30 ’25. In the deal valued at $44.00 per share,655,500 shares were bought. As a result of this transaction, BAKER BROS. ADVISORS LP now holds 6,117,295 shares worth roughly $266.96 million.
Then, Ridloff Elena sold 4,500 shares, generating $225,000 in total proceeds. Upon selling the shares at $50.00, the Director now owns 0 shares.
Before that, ELENA RIDLOFF bought 4,500 shares. Kymera Therapeutics Inc shares valued at $218,700 were divested by the Director at a price of $48.60 per share.
Morgan Stanley upgraded its Kymera Therapeutics Inc [KYMR] rating to an Overweight from a an Equal-weight in a research note published recently. A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who increased its forecast for the stock in early June from “a Neutral” to “a Buy”. BofA Securities also remained covering KYMR and has increased its forecast on June 02, 2025 with a “Buy” recommendation from previously “Neutral” rating.
Price Performance Review of KYMR
On Monday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock fall -1.09% to $43.64. Over the last five days, the stock has lost -5.72%. Kymera Therapeutics Inc shares have risen nearly 46.00% since the year began. Nevertheless, the stocks have risen 8.48% over the past one year. While a 52-week high of $53.27 was reached on 06/11/25, a 52-week low of $19.44 was recorded on 04/09/25.
Levels Of Support And Resistance For KYMR Stock
The 24-hour chart illustrates a support level at 43.14, which if violated will result in even more drops to 42.64. On the upside, there is a resistance level at 44.58. A further resistance level may holdings at 45.53.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-06-13, growing by 0.59 million shares to a total of 7.58 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 7.0 million shares. There was a rise of 7.75%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 13, 2025 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $52 price target.
